Advance implementation science methods to rapidly translate evidence-based cancer prevention and control interventions into clinical and community practice.
Organization
Implementation Science Center for Cancer Control
National – US
Educate clinicians in more isolated settings about the strengths and limitations of molecular testing and new developments in the field.
Organization
American Society of Clinical Oncology (ASCO)
National – US
Ensure quality, accuracy, and reliability of molecular biomarker testing through laboratory accreditation standards and proficiency testing.
Organization
College of American Pathologists (CAP)
National – US
International
Enable molecular testing access for eligible patients with NSCLC and other cancers that may benefit from Lilly targeted therapies through sponsored testing and site grants.
Organizations
Lilly
Loxo@Lilly
Focus Areas
Lung
Pan-cancer
National – US
Expert consensus on the clinical use of liquid biopsy in advanced NSCLC, including plasma circulating tumor DNA testing and its relationship to tissue-based testing.
Organization
International Association for the Study of Lung Cancer (IASLC)
National – US
International
Thoracic cancer education platform including many materials relevant to biomarker testing.
Organization
International Association for the Study of Lung Cancer (IASLC)
National – US
International
Educational health system QI program to improve NSCLC biomarker testing rates across participating systems.
Organization
American Cancer Society (ACS)
National – US
Enable Medicare to cover multi-cancer early detection liquid biopsy screening tests.
Organization
Prevent Cancer Foundation
National – US
Establish Medicare Local Coverage Determinations (LCDs) for molecular diagnostic tests including NGS, setting medical necessity criteria and reimbursement rates.
Organization
Centers for Medicare and Medicaid Services (CMS)
National – US
Develop and promote in person educational and peer-to-peer learning opportunities for molecular biomarker testing in oncology to promote appropriate and equitable access to high-quality guideline-concordant patient care.
Organization
Association for Molecular Pathology (AMP)
International
Develop and promulgate evidence-based guidelines and practice implementation strategies for molecular biomarker testing in oncology to promote appropriate and equitable access to high-quality guideline-concordant patient care.
Organization
Association for Molecular Pathology (AMP)
International
Develop and promote patient-facing educational resources and opportunities for molecular biomarker testing in oncology to promote appropriate and equitable access to high-quality guideline-concordant patient care.
Organization
Association for Molecular Pathology (AMP)
International
Develop and promote online and on demand educational opportunities for molecular biomarker testing in oncology to promote appropriate and equitable access to high-quality guideline-concordant patient care.
Organization
Association for Molecular Pathology (AMP)
International
Develop and promote provider-facing educational resources for molecular biomarker testing in oncology to promote and implement appropriate and equitable access to high-quality guideline-concordant patient care.
Organization
Association for Molecular Pathology (AMP)
International
Represents its membership to the federal agencies and members of Congress regarding regulatory issues impacting molecular biomarker testing in oncology, reaching out to fellow professional associations, industry and other association partners to accomplish common goals.
Organization
Association for Molecular Pathology (AMP)
National – US
Represents its membership to the federal agencies and members of Congress regarding professional and reimbursement issues impacting molecular biomarker testing in oncology, reaching out to fellow professional associations, industry and other association partners to accomplish common goals.
Organization
Association for Molecular Pathology (AMP)
National – US
Establish a 10-year federal cancer strategy emphasizing biomarker testing, precision medicine, health equity, and coordinated action to reduce cancer mortality.
Organizations
National Institutes for Health (NIH)
National Cancer Institute (NCI)
National – US
Updated in conjuction with the NCCN Treatment Guidelines, the goal of the NCCN Biomarkers Compendium® is to provide essential details for those tests which have been approved by NCCN Guideline Panels and are recommended within the NCCN Treatment Guidelines.
Organization
National Comprehensive Cancer Network (NCCN)
National – US
International
Public awareness of comprehensive biomarker testing in NSCLC.
National – US
Improve quality and reduce cost of oncology care through episode-based payment and care transformation requirements, promoting guideline-concordant cancer care.
Organization
Center for Medicare and Medicaid Innovation (CMMI)
National – US